YARD-FORCE
28.6.2024 06:13:34 CEST | Business Wire | Press release
Yard Force is excited to announce the launch of the LX PS300 Portable Power Station, a versatile and powerful battery backup solution designed for a variety of applications, from camping and outdoor activities to emergency power supply. With a battery capacity of 296Wh and peak output of 600W, the LX PS300 provides reliable and efficient power for all your electronic devices. The Yard Force LX PS300 Portable Power Station is now available for purchase on Amazon.de here.
Key Features of the Yard Force LX PS300 Portable Power Station:
- Mobile Power Supply: The LX PS300 is the ideal portable power station for camping, RV trips, outdoor activities, garden sheds, picnics, festivals, or as an emergency power supply. It offers a battery capacity of 296Wh (600W peak) and is suitable for use with electronic devices such as smartphones, tablets, and more.
- Fast Recharge Time: Compatible with separately available solar panels (LX SPP10/100W and LX SPP20/200W), the LX PS300 can be fully recharged in just 6 hours, ensuring you always have power when you need it.
- Superior Performance: Equipped with a lithium-ion battery, the LX PS300 features 2*230V outlets, 2 USB-A ports, 2 Type-C ports, and a 12V car port. Technical specifications include a peak output of 600W, dimensions of 16.5 x 20.5 x 14.5 cm, and a lightweight design weighing only 3.10 kg.
- Eco-Friendliness and Safety: The YARD FORCE Power Station is more environmentally friendly than traditional generators, as it requires no gasoline or other fuels. The integrated solar charge controller with MPPT technology maximizes charging efficiency. The Battery Management System (BMS) ensures protection against overheating, short circuits, overcurrent, and overcharging, guaranteeing maximum safety.
- Flexibility: Our innovative product line offers lightweight, portable, and green energy solutions, providing our customers with flexible and comprehensive power solutions on the go.
Customer Popularity in Germany:
The Yard Force LX PS300 Portable Power Station has gained significant popularity in the German market, with customers highly satisfied with its performance and ease of use. Available for purchase on Amazon.de, the product continues to receive positive reviews and strong demand.
For more information and to purchase the Yard Force LX PS300 Portable Power Station, visit Amazon.de.
About Yard Force:
Yard Force is a global leader in innovative garden tools and outdoor power equipment. Known for our dedication to quality, performance, and customer satisfaction, we strive to enhance the outdoor experience with our cutting-edge products. Yard Force is committed to delivering reliable and efficient solutions that meet the diverse needs of our customers.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240627113643/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release
Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b
LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 07:09:00 CEST | Press release
The deal would be part of a 360° partnership with Randstad involving: Proposed acquisition of USD 500M+ (€469M) business, primarily across Aerospace & Defence, Automotive, Utilities and BFS Five-year IT services partnership to drive AI-enabled transformation for Randstad’s India Global Capability Center Strategic talent MSP to support LTM’s expanding global workforce LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through cen
Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 07:00:00 CEST | Press release
Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom